Accession | Title | Series type(s) | Organism(s) | Samples | GDS | Supplementary | Contact | Release date |
---|---|---|---|---|---|---|---|---|
![]() |
![]() |
![]() |
||||||
GSE73893 |
Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing
|
7 |
|
Alireza Khodadadi-Jamayran | Nov 17, 2015 | |||
GSE75364 |
Reprogramming by de-bookmarking somatic transcriptional program via targeting the BET bromodomains
|
8 |
|
Alireza Khodadadi-Jamayran | Aug 22, 2016 | |||
GSE138606 |
Long non-coding RNA RP11-19E11.1 is an E2F1 target required for tumor cell proliferation and survival in basal breast cancer
|
12 |
|
Alireza Khodadadi-Jamayran | Dec 11, 2019 | |||
GSE156246 |
Ontogeny and Vulnerability of Lapatinib Drug-Tolerant Persisters in HER2-positive Breast Cancer
|
39 |
|
Alireza Khodadadi-Jamayran | Dec 13, 2021 | |||
GSE171173 |
A novel regulatory mechanism of U2 spliceosome proteostasis that controls the transcriptome and therapy response in cancer [RNAseq_CUTLL1_shSF3B1.1]
|
6 |
|
Alireza Khodadadi-Jamayran | Jan 31, 2022 | |||
GSE171174 |
A novel regulatory mechanism of U2 spliceosome proteostasis that controls the transcriptome and therapy response in cancer [RNAseq_CUTLL1_shSF3B1.2]
|
6 |
|
Alireza Khodadadi-Jamayran | Jan 31, 2022 | |||
GSE171175 |
A novel regulatory mechanism of U2 spliceosome proteostasis that controls the transcriptome and therapy response in cancer [RNAseq_CUTLL1_E7107_24hr]
|
9 |
|
Alireza Khodadadi-Jamayran | Jan 31, 2022 | |||
GSE171176 |
A novel regulatory mechanism of U2 spliceosome proteostasis that controls the transcriptome and therapy response in cancer [RNAseq_CUTLL1_E7107_15min_30m]
|
12 |
|
Alireza Khodadadi-Jamayran | Jan 31, 2022 | |||
GSE171177 |
A novel regulatory mechanism of U2 spliceosome proteostasis that controls the transcriptome and therapy response in cancer [RNAseq_CUTLL1_E7107_NMDi]
|
12 |
|
Alireza Khodadadi-Jamayran | Jan 31, 2022 | |||
GSE171178 |
A novel regulatory mechanism of U2 spliceosome proteostasis that controls the transcriptome and therapy response in cancer [RNAseq_CUTLL1_shSF3B1_MapR]
|
6 |
|
Alireza Khodadadi-Jamayran | Jan 31, 2022 | |||
GSE171179 |
A novel regulatory mechanism of U2 spliceosome proteostasis that controls the transcriptome and therapy response in cancer [TTseq_CUTLL1_E7107_24hr]
|
6 |
|
Alireza Khodadadi-Jamayran | Jan 31, 2022 | |||
GSE171180 |
A novel regulatory mechanism of U2 spliceosome proteostasis that controls the transcriptome and therapy response in cancer [TTseq_CUTLL1_E7107_15min]
|
6 |
|
Alireza Khodadadi-Jamayran | Jan 31, 2022 | |||
GSE224293 |
CRISPR-Screen Identifies Senescence-Related Genes in Human Dyskeratosis Congenita Cells
|
16 | Alireza Khodadadi-Jamayran | Aug 30, 2023 | ||||
GSE285827 |
PARP inhibitors differentially regulate immune responses in distinct genetic backgrounds of high-grade serous tubo-ovarian carcinoma
|
18 | Alireza Khodadadi-Jamayran | Jan 03, 2025 | ||||
GSE81390 |
Dpy30 Is Critical for Maintaining the Identity and Function of Adult Hematopoietic Stem Cells
|
14 |
|
Alireza Khodadadi-Jamayran | Sep 08, 2016 | |||
GSE127205 |
RNA-seq to compare gene expression profiles between Asf1a WT and Asf1a KO cells
|
8 |
|
Alireza Khodadadi-Jamayran | Nov 26, 2019 | |||
GSE127232 |
In vitro and in vivo epigenome-wide CRISPR screens in mouse KrasG12D/P53-/- (KP) lung adenocarcinoma model
|
54 |
|
Alireza Khodadadi-Jamayran | Nov 26, 2019 | |||
GSE133555 |
RNA seq to compare gene expression profiles between Npm1 WT and Npm1 knockdown cells
|
6 |
|
Alireza Khodadadi-Jamayran | Jun 22, 2020 | |||
GSE145905 |
PD-L1 Engagement on T cells Promotes Self-tolerance and Suppression of Neighboring Macrophages and Effector T cells in Cancer
|
17 |
|
Alireza Khodadadi-Jamayran | May 19, 2020 | |||
GSE157972 |
β-carotene conversion to vitamin A delays atherosclerosis progression by decreasing hepatic lipid secretion in mice
|
8 |
|
Alireza Khodadadi-Jamayran | Nov 12, 2020 |